ArticleStem cells international2026
Exosomes Derived From Mesenchymal Stem Cells Regulating Myotube Cell Atrophy via NF-κB Signaling Pathway.
Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exosomes Derived From Mesenchymal Stem Cells Regulating Myotube Cell Atrophy via NF-κB Signaling Pathway.Stem cells international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow mesenchymal stem cells (BMSCs), with their potential for multidifferentiation and self-replication, are considered effective for repairing damaged tissues. BMSCs can repair and replace damaged tissues by differentiating into effective cells and secreting some cytokines that inhibit inflammation and promote tissue repair. Recent studies suggest that BMSCs' main role in tissue repair may involve the secretion of exosomes (BMSC-Exos). Basic research has shown that exosomes can have significant effects on orthopedic diseases such as osteoarthritis, muscle tissue injury, and fractures by stimulating regeneration and reducing inflammation. However, the effect of exosomes on tumor necrosis factor (TNF-α)-induced muscle atrophy remains unclear. Therefore, this study investigated the mechanism underlying the protective effect of BMSC-Exos on TNF-α-induced C2C12 myotube atrophy. Treatment with TNF-α (20 ng/mL) for 48 h significantly reduced myotube viability and diameter, which were subsequently reversed by treatment with BMSC-Exos. BMSC-Exos treatment suppressed the expression of E3 ubiquitin ligases, including Atrogin‑1/muscle atrophy F‑box and muscle ring‑finger protein‑1 (MuRF-1). Furthermore, it increased the protein expression levels of myoblast determination protein-1 (MyoD) in TNF-α-induced myotubes. BMSC-Exos also decreased the nuclear translocation of nuclear factor-κB (NF-κB) by inhibiting the phosphorylation of κB inhibitors. These findings indicate that BMSC-Exos may protect against TNF-α-induced myotube atrophy by inhibiting the proinflammatory NF-κB pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.